Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment - Wikidata - wikimedia - TriplyDB

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

http://www.wikidata.org/entity/Q24657761

about

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Vascular Complications of Cancer Chemotherapy Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients More sound cancer therapy biomarker development with active noise control.Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Bayesian inference for longitudinal data with non-parametric treatment effects.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Epidemiology and risk factors for kidney cancer.A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population.Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis Cardiotoxicity of molecularly targeted agents Emerging molecular classification in renal cell carcinoma: implications for drug development.Antiangiogenic therapy for glioma.Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.Management of antiangiogenic therapy-induced hypertension.Relating human genetic variation to variation in drug responses.Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1 Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib.Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

P2860

Q24595773-EC7B01AF-FF4F-487B-B4BA-5C63D8BAED63 Q26752752-D36BB74A-8C02-43B3-9BC7-34202CC75BC2 Q26766269-19FC1DA6-D28B-4BFB-8FEA-D3CD7750A7A7 Q28080163-989F07D8-E72F-4508-AE1B-DC5C2A2832E5 Q30442454-00D7EC95-9836-4B78-A6DF-A2C74B564E2B Q30486078-676D35C2-442B-4D45-8E6D-D89ED808921D Q30587082-4AC60F8C-5184-4A08-850C-F0279CA5119D Q30703262-B8345699-4D97-4274-AA0A-8F8673A12BCC Q33684042-9ED04F21-DD73-4D31-9DE2-E55677A2E228 Q33828690-06D355FF-63CE-4CDE-A3B5-FB30DC8DDF3A Q34122191-D8417313-AE99-4B81-B059-F309AB6C95DE Q34245458-806FE32B-B263-4EA4-8704-B150BA99FDFC Q34449963-8EE66FF0-594B-48B9-BA3E-7F503F25A965 Q34464397-947163C0-6C5E-4FE3-8AC2-9495435F5679 Q34627959-FBE6192C-75BA-4881-A79A-4A036A30A732 Q34771265-95594653-BE99-43F3-B09A-21CD34AC190F Q34803030-B2C193CA-328C-4423-B436-FB6A2B3E0CE3 Q34943606-B44048B4-7196-4528-A0F6-D610226C4F2A Q35052037-68D7ED20-8580-4D0C-B5D4-0A6CB15A3BF2 Q35068932-B040DD6D-52FB-41F7-95F1-0DDDA3DB55E9 Q35187848-302261C3-4635-4CD1-95C7-F1463647A914 Q35346619-0F239EF9-0873-4DCA-85FA-0D19B69DA907 Q35536088-54E550CE-57A7-407D-956C-034FEB660C34 Q35584752-21F59FCF-4F1A-4A26-AB2F-C3E26F1DFEDF Q35642373-4E4FE018-0125-4709-B288-0CC482D62467 Q35758408-09BFB1C2-CA15-4898-A6E4-67DFD4F9F25E Q35878459-B8BB65D3-E225-4216-94E4-0B4B4DE1DAA7 Q36084718-A28C797C-CEAA-49D0-A5E8-E5AF3DF2581E Q36101999-C49B198F-84D3-4205-9B68-430132892F99 Q36136849-0E1E26E1-727C-43A2-8C13-4305331E772F Q36170252-15DF31B5-8C5B-432B-BB15-AB86312E6CBD Q36252524-4BC0F869-0120-4C73-A752-EAB8719CA4D3 Q36627125-7B24C54D-965F-4907-A893-45B458890B3D Q36751861-D3D78F49-6C80-46A3-9441-618B5D805963 Q37128767-109D8C1A-9723-4BC0-8AF5-F70A8C329354 Q37655483-C22F5D54-9121-4D3E-9A22-CDA00D020747 Q37656300-F80400D8-02B1-4E7D-ADEC-8B033F6FD1E9 Q37700647-B022BFBB-E3B7-44D2-8A36-F4B63D776423 Q37935596-18922998-BCE3-4966-A791-12FC9CB4BF6F Q37963823-80FC9FC3-AC34-426D-99A0-CC4FB872C171

P2860

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

http://www.wikidata.org/entity/Q24657761

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Ambulatory monitoring detects ...... on the first day of treatment

@ast

Ambulatory monitoring detects ...... on the first day of treatment

@en

Ambulatory monitoring detects ...... on the first day of treatment

@nl

type

label

Ambulatory monitoring detects ...... on the first day of treatment

@ast

Ambulatory monitoring detects ...... on the first day of treatment

@en

Ambulatory monitoring detects ...... on the first day of treatment

@nl

prefLabel

Ambulatory monitoring detects ...... on the first day of treatment

@ast

Ambulatory monitoring detects ...... on the first day of treatment

@en

Ambulatory monitoring detects ...... on the first day of treatment

@nl

P1433

Q24657761-19319380-C08A-4A71-A1AE-AF23733DF973

P1476

Q24657761-6C01BE6D-16C4-4314-BAE1-D68930D5BB4F

P2093

Q24657761-15238E9E-1D5C-436D-96D5-A38437FC4184

Q24657761-19D4922F-E973-4C0F-B1AF-8466BAFE233E

Q24657761-396933A6-DF1D-45E1-BF08-D5994D199403

Q24657761-656AA620-F4FD-4D92-A3CB-300A86C47068

Q24657761-73975E71-D9A6-4333-A894-974DDFD3B27F

Q24657761-7BBD4C93-A050-4FDA-A9F0-11B102D0E667

Q24657761-813C6A76-A133-4867-8302-27CD0D2547C4

Q24657761-81D05B7B-6D8B-4AAD-AF2F-055BE8FFDE41

Q24657761-B188EFEF-AF39-4586-BC03-C3CE8874AD64

P2860

Q24657761-02EA0CF3-7B66-42C4-9884-0EBDAC6E5FB7

Q24657761-17E0DD52-06BF-46A7-A908-5B9F4CFC805D

Q24657761-1F7A9EFA-0CF7-4842-8518-B12B949591F3

Q24657761-298DE595-1643-4C7A-A2DF-81FD94740784

Q24657761-2DDC70E4-2831-40C4-BEB1-A36F4342F38D

Q24657761-35262E3A-BADC-4836-B5E6-F8DA23ABB1EF

Q24657761-3C30EE3C-FCD7-491B-976E-75CFDC351DCD

Q24657761-3CEC0575-D98F-4653-9ECA-10B00C8F93CC

Q24657761-454BFF8B-0352-4320-AF05-DDB81712D47F

Q24657761-481E888A-E08C-4675-80BC-1227B6496D0D

P304

Q24657761-5BDDE7A6-8C44-4F8E-855A-95E526BF272C

P31

Q24657761-CDD44604-1057-4DB6-886B-8E13320EF7D7

P3181

Q24657761-ADA79796-AA18-4D1F-A30F-1BFC3FAE11AD

P356

Q24657761-5B8E473D-0F3D-495F-9084-8B2640F4769C

P407

Q24657761-EBD02F10-062D-4745-AE80-6CDBE39C14E2

P433

Q24657761-E3E2E909-ED5C-49D0-A706-62A12AF4185F

P478

Q24657761-D174C7D4-166D-4956-B7E6-A53BC388D912

P50

Q24657761-3C73EE59-727E-47C1-B61A-BF0D032F0FB1

P577

Q24657761-1747F2DA-C60C-455E-9AAB-F09842782BEC

P698

Q24657761-639B5D66-5F9C-4D59-98ED-56842241BE70

P932

Q24657761-548AE67E-F44B-496D-9BBA-5D6BDDEAC395

P3181

P356

1078-0432.CCR-09-0058

P1433

Clinical Cancer Research

P1476

Ambulatory monitoring detects ...... on the first day of treatment

@en

P2093

Henry R Black

http://www.w3.org/2001/XMLSchema#string

Kristen E Kasza

http://www.w3.org/2001/XMLSchema#string

Kristin Moshier

http://www.w3.org/2001/XMLSchema#string

Laura Sit

http://www.w3.org/2001/XMLSchema#string

Michael L Maitland

http://www.w3.org/2001/XMLSchema#string

Samir D Undevia

http://www.w3.org/2001/XMLSchema#string

Theodore Karrison

http://www.w3.org/2001/XMLSchema#string

Walter M Stadler

http://www.w3.org/2001/XMLSchema#string

William J Elliott

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

Sorafenib in advanced clear-cell renal-cell carcinoma

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

Sunitinib in patients with metastatic renal cell carcinoma.

P304

6250-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2042633

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-09-0058

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19773379

http://www.w3.org/2001/XMLSchema#string

P932

2756980

http://www.w3.org/2001/XMLSchema#string